Tandem Diabetes Care | TNDM - Selling And Administration Expenses


Tandem Diabetes Care reported $94.52M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
Align Technology USD 417.8M 30.89M Sep/2025
AtriCure USD 78.23M 158K Sep/2025
Baxter International USD 708M 10M Sep/2025
Becton, Dickinson and Co. USD 1.37B 46M Sep/2025
Boston Scientific USD 1.74B 25M Sep/2025
Cooper Companies USD 419.2M 12M Sep/2025
Dexcom USD 331.4M 3.4M Sep/2025
Edwards Lifesciences USD 514.6M 12.6M Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Globus Medical USD 313.6M 9.98M Sep/2025
ICU Medical USD 152.77M 6.62M Sep/2025
Insulet USD 315.2M 61.9M Sep/2025
Integra LifeSciences USD 169.05M 10.84M Sep/2025
Intuitive Surgical USD 687.1M 113.8M Dec/2025
J&J USD 6.75B 831M Dec/2025
Masimo USD 116.4M 20.5M Sep/2025
Medtronic 2.97B 159M Sep/2025
Merit Medical Systems USD 107.38M 5.72M Sep/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Stryker USD 2.14B 150M Dec/2025
Tandem Diabetes Care USD 94.52M 1.47M Sep/2025
Teleflex USD 281.76M 66.68M Sep/2025
Zimmer Biomet Holdings USD 811.4M 3.4M Sep/2025